Frequent mutations in acetylation and ubiquitination sites suggest novel driver mechanisms of cancer

Genome Medicine

Volumn 8, Issue 1, 2016, Pages

  Narayan, Soumil ^a   Bader, Gary D ^a   Reimand, Jüri ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; ONCOPROTEIN; PROTEIN AKT1; PROTEIN P53; UNCLASSIFIED DRUG; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CANCER SURVIVAL; CHROMATIN; CONTROLLED STUDY; GENE MUTATION; GENE TARGETING; GENETIC CONSERVATION; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASM; MOLECULAR EVOLUTION; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; SOMATIC MUTATION; UBIQUITINATION; ACETYLATION; BIOLOGY; GENE REGULATORY NETWORK; GENETIC DATABASE; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MUTATION; MUTATION RATE; NEOPLASM; PROCEDURES; PROTEIN PROCESSING; SURVIVAL ANALYSIS;

ACETYLATION; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; GENE REGULATORY NETWORKS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; MUTATION RATE; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN INTERACTION MAPS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SURVIVAL ANALYSIS; UBIQUITINATION;

EID: 85007518092     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/s13073-016-0311-2     Document Type: Article

References (78)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell.2011;144(5):646-74. doi:10.1016/j.cell.2011.02.013.
2. Northcott PA, Shih DJH, Peacock J, Garzia L, Sorana Morrissy A, Zichner T, et al.Subgroup-specific structural variation across 1,000 medulloblastoma genomes.Nature. 2012;488(7409):49-56. doi:10.1038/nature11327.
3. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349(21):2042-54. doi:10.1056/NEJMra023075.
4. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683-92.doi:10.1016/j.cell.2007.01.029.
5. Network TCGAR, Weinstein JN, Collisson EA, Mills GB, Shaw KRM,Ozenberger BA, et al. The Cancer Genome Atlas Pan-Cancer analysis project.Nat Genet. 2013;45(10):1113-20.
6. Gonzalez-Perez A, Mustonen V, Reva B, Ritchie GRS, Creixell P, Karchin R, et al.Computational approaches to identify functional genetic variants in cancer genomes. Nat Methods. 2013;10(8):723-9. doi:10.1038/nmeth.2562.
7. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW.Cancer genome landscapes. Science. 2013;339(6127):1546-58. doi:10.1126/science.1235122.
8. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al.Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499(7457):214-8. doi:10.1038/nature12213.
9. Dees ND, Zhang Q, Kandoth C, Wendl MC, Schierding W, Koboldt DC, et al.MuSiC: Identifying mutational significance in cancer genomes. Genome Res.2012;22(8):1589-98. doi:10.1101/gr.134635.111.
10. Salk JJ, Fox EJ, Loeb LA. Mutational heterogeneity in human cancers: origin and consequences. Annu Rev Pathol. 2010;5:51-75. doi:10.1146/annurevpathol-121808-102113.
11. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Biankin AV,et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415-21. doi:10.1038/nature12477.
12. Fousteri M, Mullenders LHF. Transcription-coupled nucleotide excision repair in mammalian cells: molecular mechanisms and biological effects. Cell Res.2008;18(1):73-84. doi:10.1038/cr.2008.6.
13. Stamatoyannopoulos JA, Adzhubei I, Thurman RE, Kryukov GV, Mirkin SM,Sunyaev SR. Human mutation rate associated with DNA replication timing.Nat Genet. 2009;41(4):393-5. doi:10.1038/ng.363.
14. Schuster-Bockler B, Lehner B. Chromatin organization is a major influence on regional mutation rates in human cancer cells. Nature. 2012;488(7412):504-7.
15. Reimand J, Hui S, Jain S, Law B, Bader GD. Domain-mediated protein interaction prediction: From genome to network. FEBS Lett. 2012;586(17):2751-63. http://dx.doi.org/10.1016/j.febslet.2012.04.027.
16. Pawson T. Protein modules and signalling networks. Nature. 1995;373(6515):573-80. doi:10.1038/373573a0.
17. Reimand J, Bader GD. Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers. Mol Syst Biol. 2013;9:637. doi:10.1038/msb.2012.68.
18. Reimand J, Wagih O, Bader GD. The mutational landscape of phosphorylation signaling in cancer. Sci Rep. 2013;3:2651. doi:10.1038/srep02651.
19. Tamborero D, Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, Kandoth C,Reimand J, et al. Comprehensive identification of mutational cancer driver genes across 12 tumor types. Sci Rep. 2013;3:2650. doi:10.1038/srep02650.
20. Liu Z, Cao J, Gao X, Zhou Y, Wen L, Yang X, et al. CPLA 1.0: an integrated database of protein lysine acetylation. Nucleic Acids Res. 2010;39(Database):D1029-34. doi:10.1093/nar/gkq939.
21. Gao T, Liu Z, Wang Y, Cheng H, Yang Q, Guo A, et al. UUCD: a family-based database of ubiquitin and ubiquitin-like conjugation. Nucleic Acids Res.2012;41(D1):D445-51. doi:10.1093/nar/gks1103.
22. Hornbeck PV, Kornhauser JM, Tkachev S, Zhang B, Skrzypek E, Murray B, et al.PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res. 2011;40(D1):D261-70.doi:10.1093/nar/gkr1122.
23. Hunter T. The age of crosstalk: phosphorylation, ubiquitination, and beyond.Mol Cell. 2007;28(5):730-8. doi:10.1016/j.molcel.2007.11.019.
24. Reimand J, Wagih O, Bader GD. Evolutionary constraint and disease associations of post-translational modification sites in human genomes.PLoS Genet. 2015;11(1):e1004919. doi:10.1371/journal.pgen.1004919.
25. Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293(5532):1074-80. doi:10.1126/science.1063127.
26. Füllgrabe J, Kavanagh E, Joseph B. Histone onco-modifications. Oncogene.2011;30(31):3391-403. doi:10.1038/onc.2011.121.
27. Plass C, Pfister SM, Lindroth AM, Bogatyrova O, Claus R, Lichter P.Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet. 2013;14(11):765-80.doi:10.1038/nrg3554.
28. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene. 2005;363:15-23. doi:10.1016/j.gene.2005.09.010.
29. Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol. 2010;3:5.
30. Welchman RL, Gordon C, Mayer RJ. Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat Rev Mol Cell Biol. 2005;6(8):599-609.doi:10.1038/nrm1700.
31. Ikeda F, Dikic I. Atypical ubiquitin chains: new molecular signals. 'Protein Modifications: Beyond the Usual Suspects' Review Series. EMBO Rep. 2008;9(6):536-42. doi:10.1038/embor.2008.93.
32. Hoeller D, Dikic I. Targeting the ubiquitin system in cancer therapy. Nature.2009;458(7237):438-44. doi:10.1038/nature07960.
33. Shah M, Denton E, Arrowsmith C, Lupien M, Schapira M. A global assessment of cancer genomic alterations in epigenetic mechanisms.Epigenetics Chromatin. 2014;7(1):29.
34. Gonzalez-Perez A, Jene-Sanz A, Lopez-Bigas N. The mutational landscape of chromatin regulatory factors across 4,623 tumor samples. Genome Biol.2013;14(9):r106. doi:10.1186/gb-2013-14-9-r106.
35. Hudson TJ, Anderson W, Aretz A, Barker AD, Bell C, Bernabé RR, et al.International network of cancer genome projects. Nature. 2010;464(7291):993-8. doi:10.1038/nature08987.
36. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):e164. doi:10.1093/nar/gkq603.
37. Punta M, Coggill PC, Eberhardt RY, Mistry J, Tate J, Boursnell C, et al. The Pfam protein families database. Nucleic Acids Res. 2012;40(Database issue):D290-301. doi:10.1093/nar/gkr1065.
38. Letunic I, Doerks T, Bork P. SMART 7: recent updates to the protein domain annotation resource. Nucleic Acids Res. 2012;40(Database issue):D302-5. doi:10.1093/nar/gkr931.
39. Ward JJ, McGuffin LJ, Bryson K, Buxton BF, Jones DT. The DISOPRED server for the prediction of protein disorder. Bioinformatics. 2004;20(13):2138-9.doi:10.1093/bioinformatics/bth195.
40. Siepel A, Bejerano G, Pedersen JS, Hinrichs AS, Hou M, Rosenbloom K, et al.Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res. 2005;15(8):1034-50. doi:10.1101/gr.3715005.
41. Tamborero D, Gonzalez-Perez A, Lopez-Bigas N. OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes.Bioinformatics. 2013;29(18):2238-44. doi:10.1093/bioinformatics/btt395.
42. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015;43(Database issue):D805-11. doi:10.1093/nar/gku1075.
43. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Geneontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000;25(1):25-9. doi:10.1038/75556.
44. Croft D. Building models using reactome pathways as templates. In:Schneider MV, editor. Silico systems biology. Methods in molecular biology.New York: Humana Press; 2013. p. 273-83.
45. Ruepp A, Waegele B, Lechner M, Brauner B, Dunger-Kaltenbach I, Fobo G, et al.CORUM: the comprehensive resource of mammalian protein complexes-2009.Nucleic Acids Res. 2009;38(Database):D497-501. doi:10.1093/nar/gkp914.
46. Reimand J, Arak T, Vilo J. g:Profiler-a web server for functional interpretation of gene lists (2011 update). Nucleic Acids Res. 2011;39(suppl):W307-15.doi:10.1093/nar/gkr378.
47. Merico D, Isserlin R, Stueker O, Emili A, Bader GD, Ravasi T. Enrichment Map: A network-based method for gene-set enrichment visualization and interpretation.PLoS One. 2010;5(11):e13984. doi:10.1371/journal.pone.0013984.
48. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al.Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498-504.doi:10.1101/gr.1239303.
49. Chatr-Aryamontri A, Breitkreutz BJ, Oughtred R, Boucher L, Heinicke S, Chen D, et al. The BioGRID interaction database: 2015 update. Nucleic Acids Res.2015;43(Database issue):D470-8. doi:10.1093/nar/gku1204.
50. Du Y, Xu N, Lu M, Li T. hUbiquitome: a database of experimentally verified ubiquitination cascades in humans. Database. 2011;2011:bar055. doi:10.1093/database/bar055.
51. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502(7471):333-9.
52. Leung A, Bader GD, Reimand J. HyperModules: identifying clinically and phenotypically significant network modules with disease mutations for biomarker discovery. Bioinformatics. 2014;30(15):2230-2. doi:10.1093/bioinformatics/btu172.
53. Miller ML, Jensen LJ, Diella F, Jørgensen C, Tinti M, Li L, et al. Linear motifatlas for phosphorylation-dependent signaling. Sci Signal. 2008;1(35):ra2.
54. Basu A, Rose KL, Zhang J, Beavis RC, Ueberheide B, Garcia BA, et al.Proteome-wide prediction of acetylation substrates. Proc Natl Acad Sci U S A. 2009;106(33):13785-90. doi:10.1073/pnas.0906801106.
55. Zeng L, Zhang Q, Gerona-Navarro G, Moshkina N, Zhou M-M. Structural basis of site-specific histone recognition by the bromodomains of human coactivators PCAF and CBP/p300. Structure. 2008;16(4):643-52.doi:10.1016/j.str.2008.01.010.
56. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding nonsynonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009;4(7):1073-81. doi:10.1038/nprot.2009.86.
57. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, et al.Amethod and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248-9. doi:10.1038/nmeth0410-248.
58. Chun S, Fay JC. Identification of deleterious mutations within three human genomes. Genome Res. 2009;19(9):1553-61. doi:10.1101/gr.092619.109.
59. Pollard KS, Hubisz MJ, Rosenbloom KR, Siepel A. Detection of nonneutral substitution rates on mammalian phylogenies. Genome Res. 2010;20(1):110-21.doi:10.1101/gr.097857.109.
60. Schwarz JM, Rödelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods.2010;7(8):575-6. doi:10.1038/nmeth0810-575.
61. Liu X, Jian X, Boerwinkle E. dbNSFP v2.0: A database of human nonsynonymous SNVs and their functional predictions and annotations. Hum Mutat. 2013;34(9):E2393-402. doi:10.1002/humu.22376.
62. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, et al.A census of human cancer genes. Nat Rev Cancer. 2004;4(3):177-83.doi:10.1038/nrc1299.
63. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al.The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17(3):225-34. doi:10.1016/j.ccr.2010.01.020.
64. Lee J-O, Yang H, Georgescu M-M, Di Cristofano A, Maehama T, Shi Y, et al.Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell.1999;99(3):323-34. doi:10.1016/s0092-8674(00)81663-3.
65. Okumura K, Mendoza M, Bachoo RM, DePinho RA, Cavenee WK, Furnari FB. PCAF modulates PTEN activity. J Biol Chem. 2006;281(36):26562-8.doi:10.1074/jbc.M605391200.
66. Chang J, Davis-Dusenbery BN, Kashima R, Jiang X, Marathe N, Sessa R, et al.Acetylation of p53 stimulates miRNA processing and determines cell survival following genotoxic stress. EMBO J. 2013;32(24):3192-205. doi:10.1038/emboj.2013.242.
67. Yang W-L, Wang J, Chan C-H, Lee S-W, Campos AD, Hur L, et al. The E3 Ligase TRAF6 regulates Akt ubiquitination and activation. Science. 2009;325(5944):1134-8. doi:10.1126/science.1175065.
68. Yang W-L, Wu C-Y, Wu J, Lin H-K. Regulation of Akt signaling activation by ubiquitination. Cell Cycle. 2010;9(3):487-97.
69. Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and nonbrainstem glioblastomas. Nat Genet. 2012;44(3):251-3. doi:10.1038/ng.1102.
70. Bender S, Tang Y, Lindroth AM, Hovestadt V, Jones David TW, Kool M, et al.Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell. 2013;24(5):660-72. doi:10.1016/j.ccr.2013.10.006.
71. Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al.Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365(15):1384-95. doi:10.1056/NEJMoa1103283.
72. Song EJ, Werner SL, Neubauer J, Stegmeier F, Aspden J, Rio D, et al. The Prp19 complex and the Usp4Sart3 deubiquitinating enzyme control reversible ubiquitination at the spliceosome. Genes Dev. 2010;24(13):1434-47. doi:10.1101/gad.1925010.
73. Bellare P, Small EC, Huang X, Wohlschlegel JA, Staley JP, Sontheimer EJ. A role for ubiquitin in the spliceosome assembly pathway. Nat Struct Mol Biol.2008;15(5):444-51. doi:10.1038/nsmb.1401.
74. Maguire SL, Leonidou A, Wai P, Marchio C, Ng CK, Sapino A, et al. SF3B1 mutations constitute a novel therapeutic target in breast cancer. J Pathol.2015;235(4):571-80. doi:10.1002/path.4483.
75. Wasch R, Engelbert D. Anaphase-promoting complex-dependent proteolysis of cell cycle regulators and genomic instability of cancer cells. Oncogene.2005;24(1):1-10.
76. Shema E, Tirosh I, Aylon Y, Huang J, Ye C, Moskovits N, et al. The histone H2B-specific ubiquitin ligase RNF20/hBRE1 acts as a putative tumor suppressor through selective regulation of gene expression. Genes Dev.2008;22(19):2664-76. doi:10.1101/gad.1703008.
77. Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stutz AM, et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature.2014;506(7489):445-50. doi:10.1038/nature13108.
78. MacArthur DG, Manolio TA, Dimmock DP, Rehm HL, Shendure J, Abecasis GR, et al. Guidelines for investigating causality of sequence variants in human disease. Nature. 2014;508(7497):469-76. doi:10.1038/nature13127.